{"id":55165,"date":"2024-11-27T18:03:16","date_gmt":"2024-11-27T18:03:16","guid":{"rendered":"https:\/\/newonclusivstg.wpengine.com\/?p=55165"},"modified":"2026-05-21T13:10:21","modified_gmt":"2026-05-21T13:10:21","slug":"the-lasting-impact-of-covid-19-on-pharmaceutical-industry","status":"publish","type":"post","link":"https:\/\/onclusive.com\/en-gb\/resources\/blog\/the-lasting-impact-of-covid-19-on-pharmaceutical-industry\/","title":{"rendered":"The lasting impact of COVID-19 on Pharmaceutical Industry Media Coverage and Consumer Sentiment"},"content":{"rendered":"\n<section\n    class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--copy_with_image  \">\n\t\t\t\t\t<div class=\"post_content--copy_with_image-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<p><span style=\"font-weight: 400;\">Our media monitoring and social listening analysis, (October 2023 to October 2024), has uncovered a transformation in pharmaceutical industry media coverage. It demonstrates that COVID-related subjects account for 16.4% of industry dialogue. 11.2% focused on pandemic aftermath and 5.2% specifically addressing vaccinations. Most notably, 98% of these discussions carry negative sentiment, centring on rumours, legal challenges, and manufacturer grievances.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><b>Key Events Shaping Pharmaceutical Industry Media Coverage<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Our media monitoring analysis shows how major announcements and developments shaped pharmaceutical coverage throughout the year:<\/span><\/p>\n<h3><b>COVID-Related Milestones:<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>October 2023:<\/b> <a href=\"https:\/\/www.bbc.co.uk\/news\/health-66983060\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Nobel Prize<\/span><\/a><span style=\"font-weight: 400;\"> awarded to scientists behind mRNA COVID vaccines, generating substantial industry-wide discussion.<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>May 2024:<\/b> <a href=\"https:\/\/www.theguardian.com\/business\/article\/2024\/may\/08\/astrazeneca-withdraws-covid-19-vaccine-worldwide-citing-surplus-of-newer-vaccines\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">AstraZeneca withdraws COVID vaccine<\/span><\/a><span style=\"font-weight: 400;\"> worldwide, citing surplus of newer vaccines<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h3><b>Strategic Corporate Developments:<\/b><\/h3>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>December 2023<\/b><span style=\"font-weight: 400;\">:<\/span><a href=\"https:\/\/www.yahoo.com\/news\/pfizer-gets-ok-43-billion-120551535.html\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> Pfizer closes Seagen deal<\/span><\/a><span style=\"font-weight: 400;\">, creates new cancer division<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>January 2024:<\/b><span style=\"font-weight: 400;\"> Merck acquires <\/span><a href=\"https:\/\/www.biospace.com\/merck-to-buy-cancer-immunotherapy-biotech-harpoon-for-680-million\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">cancer immunotherapy biotech Harpoon<\/span><\/a> <b>March 2024:<\/b><span style=\"font-weight: 400;\"> Boehringer introduces <\/span><a href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/boehringer-cut-out-of-pocket-costs-inhalers-35-2024-03-07\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">$35 monthly cap<\/span><\/a><span style=\"font-weight: 400;\"> on inhaler costs<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>March 2024:<\/b><a href=\"https:\/\/www.businesswire.com\/news\/home\/20240226565897\/en\/Takeda-and-Biological-E.-Limited-Collaborate-to-Accelerate-Access-to-Dengue-Vaccine-in-Endemic-Areas\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">Takeda partners with India&#8217;s Biological E.<\/span><\/a><span style=\"font-weight: 400;\"> to expand dengue vaccine access<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>September 2024:<\/b><span style=\"font-weight: 400;\"> Merck announces <\/span><a href=\"https:\/\/www.forbes.com\/sites\/greatspeculations\/2024\/09\/06\/why-did-merck-stock-rise-65\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">65% stock rise<\/span><\/a><span style=\"font-weight: 400;\"> and projected 5% annual sales growth<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">These events and their resulting coverage patterns demonstrate how both COVID-related news and corporate developments continue to shape pharmaceutical industry visibility and public sentiment.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><b>Weight-Loss Breakthroughs in the Shadow of COVID-19<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">GLP-1 medications represent a significant medical advance. And they\u2019ve been featured heavily in pharmaceutical industry media coverage this year (social and mainstream). But their commercial achievements continue to be eclipsed by the COVID-19 aftermath.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Our <\/span><a href=\"https:\/\/onclusive.com\/en-gb\/what-we-do\/monitoring\/social-listening\/\"><span style=\"font-weight: 400;\">social listening analysis <\/span><\/a><span style=\"font-weight: 400;\">demonstrates a striking disparity. Medications such as Ozempic (242,244 mentions) and Wegovy (137,835 mentions) lead conversations about prescription treatments. However, they account for just 9% of overall pharmaceutical industry discussions &#8211; less than half the volume of COVID-related discussions.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The sentiment surrounding this topic tells a compelling story: discussions around weight-loss medications predominantly focus on clinical efficacy and patient outcomes (17% of conversations). This stands in marked contrast to the persistent negativity surrounding COVID-related topics.\u00a0<\/span><\/p>\n<p><b>To find out more about the media impact of GLP-1 weight-loss medications over the last 12 months, <a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/pharma-industry-media-analysis\/\">download our full <\/a><\/b><b>pharmaceutical industry report.<\/b><\/p>\n<h2><b>Public Sentiment Surrounding Pharmaceutical Companies<\/b><\/h2>\n<h3><b>Pfizer Dominates Pharmaceutical Industry Media Coverage<\/b><b><br \/>\n<\/b><b><br \/>\n<\/b><span style=\"font-weight: 400;\">Pfizer leads pharmaceutical conversations with 13.9 million social media mentions and 944,000 mainstream media mentions.<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">This massive volume of discussion has been significantly shaped by COVID-19. Our analysis shows that <\/span><b>53% <\/b><span style=\"font-weight: 400;\">of all Pfizer-related conversations focus negatively on COVID vaccines. Unlike traditional medication discussions where <\/span><b>87.4%<\/b><span style=\"font-weight: 400;\"> of mentions reference drug names only. COVID has created a new pattern &#8211; people mainly refer to \u2018Pfizer&#8217;s COVID vaccine\u2019 rather than the product name Comirnaty, which appears in only <\/span><b>5.5%<\/b><span style=\"font-weight: 400;\"> of vaccine discussions.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The intensity of COVID-related discussions is reflected in Pfizer&#8217;s top hashtags:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">#Pfizer leads with 272,945 mentions<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">#Moderna follows at 95,599 mentions<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">#Covid19 ranks third with 92,859 mentions\u00a0<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">This interconnected pattern of vaccine-related hashtags demonstrates how deeply COVID discussions are embedded in Pfizer&#8217;s public perception.\u00a0<\/span><\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" fetchpriority=\"high\" class=\"aligncenter size-full wp-image-55180\" src=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/11\/unnamed-6.png\" alt=\"Pharma company social media and news coverage: Pfizer leads with 13.9M social mentions in 2024 analysis\" width=\"512\" height=\"109\" srcset=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/11\/unnamed-6.png 512w, https:\/\/onclusive.com\/wp-content\/uploads\/2024\/11\/unnamed-6-300x64.png 300w\" sizes=\"(max-width: 639px) 98vw, (max-width: 1199px) 64vw, 512px\" \/><\/p>\n<h3><b>AstraZeneca&#8217;s Complex Vaccination Legacy<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">With 2.3 million social media mentions and 575,000 mainstream media mentions, AstraZeneca faces the industry&#8217;s strongest vaccine-related backlash. Their May 2024 worldwide vaccine withdrawal sparked intense discussion, with 56% of all mentions focusing negatively on COVID vaccines &#8211; the highest proportion among major pharmaceutical companies. This overwhelming focus on vaccines persists in their social media footprint, with #Covid and #vaccine ranking among their top 5 hashtags.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">While the company continues to advance other key treatments like Imfinzi and Tagrisso for cancer, and Farxiga for Type II diabetes, these positive developments struggle to overcome vaccine-related sentiment.<\/span><\/p>\n<h3><b><br \/>\n<\/b><b>Merck&#8217;s Positive Narrative in Modern Medicine<\/b><b><br \/>\n<\/b><span style=\"font-weight: 400;\"><br \/>\n<\/span><span style=\"font-weight: 400;\">A closer look at Merck &amp; Co. reveals a different narrative. Unlike the vaccine controversies surrounding other companies, Merck generates primarily positive healthcare-focused conversations. As the top pharmaceutical company in terms of 2023 sales, their coverage is focused on breakthrough treatments. Their cancer medication Keytruda has become the industry&#8217;s bestseller, surpassing Humira. Discussions also highlight their Gardasil vaccine and diabetes medication Januvia.\u00a0<\/span><\/h3>\n<p>&nbsp;<\/p>\n<h2><b>Mainstream Media shows Different Priorities<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Whilst social media channels remain preoccupied with COVID-19 controversies, our mainstream <\/span><a href=\"https:\/\/onclusive.com\/what-we-do\/monitoring\/media-monitoring\/\"><span style=\"font-weight: 400;\">media monitoring<\/span><\/a><span style=\"font-weight: 400;\"> analysis reveals distinctly different editorial priorities:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Clinical trials lead coverage (9.6%), reflecting industry innovation focus<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Regulatory body interactions rank second (6.7%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Partnerships and collaborations command significant attention (5.6%)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Oncology developments maintain steady coverage (4.3%)<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">This contrast between mainstream media focus and social media discussions highlights the gap between industry developments and public perception. While traditional media highlights scientific progress and regulatory compliance, social conversations remain dominated by COVID-related concerns.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><b>The Evolution of Public Dialogue Surrounding Pharma<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Our social listening analysis (58 pharma companies and 242 medications) reveals a stark contrast between traditional medication discussions and COVID vaccine conversations. This shift represents a fundamental change in how the public engages with pharmaceutical brands.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Traditional patterns show that 87.4% of posts and comments typically mention medication names, with only 0.6% connecting those to their manufacturers. This disconnect is evident even with breakthrough treatments &#8211; only 3% of conversations about GLP-1 medications like Ozempic and Wegovy mention their manufacturer, Novo Nordisk.<\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-55173\" src=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/11\/unnamed-5.png\" alt=\"Chart shows 87.4% consumers mention drug names only vs 0.6% who mention drug manufacturers in pharma discussions\" width=\"512\" height=\"194\" srcset=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/11\/unnamed-5.png 512w, https:\/\/onclusive.com\/wp-content\/uploads\/2024\/11\/unnamed-5-300x114.png 300w\" sizes=\"(max-width: 639px) 98vw, (max-width: 1199px) 64vw, 512px\" \/><\/p>\n<h3><b>The Transformation in Vaccine Conversations<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">COVID-19 vaccines broke this pattern. Only <\/span><b>5.5%<\/b><span style=\"font-weight: 400;\"> of consumers mention specific vaccine names such as Comirnaty. Instead, <\/span><b>68%<\/b><span style=\"font-weight: 400;\"> reference manufacturer vaccines directly. They say \u2018Pfizer&#8217;s COVID vaccine\u2019 rather than the product name.<\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-55166\" src=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/11\/unnamed-4.png\" alt=\"Vaccine discussion analysis: 68.5% mention manufacturer name vs only 5.5% using vaccine brand names\" width=\"512\" height=\"185\" srcset=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/11\/unnamed-4.png 512w, https:\/\/onclusive.com\/wp-content\/uploads\/2024\/11\/unnamed-4-300x108.png 300w\" sizes=\"(max-width: 639px) 98vw, (max-width: 1199px) 64vw, 512px\" \/><\/p>\n<h2><b>Looking Forward: Restoring Trust in the Pharma Industry<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The pharmaceutical industry faces unprecedented challenges in rebuilding public trust. Our analysis suggests several critical strategies:<\/span><\/p>\n<ul>\n<li aria-level=\"1\"><b>Strategic Communications<\/b><\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Implement transparent messaging protocols<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Balance corporate visibility with medicine-focused communication<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Proactively address public concerns<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Leverage successful communication strategies from industry leaders<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<\/ul>\n<ul>\n<li aria-level=\"1\"><b>Reputation Enhancement<\/b><\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Build on successful communication models from companies like Merck<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Highlight breakthrough treatments while acknowledging public concerns<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Develop clear crisis communication protocols<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\"><\/p>\n<p><\/span><\/p>\n<ul>\n<li aria-level=\"1\"><b>Future Priorities<\/b><\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Maintain transparency about both COVID and non-COVID developments<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Leverage positive coverage of breakthrough treatments<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Build sustainable trust through consistent, honest engagement<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h2><b>Multi-Channel Analysis of Pharmaceutical Industry Media Coverage<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Our mainstream media analysis reveals distinct patterns in how different media channels cover the pharmaceutical industry. While social media amplifies public sentiment, traditional media channels show different priorities:<\/span><\/p>\n<p><b>&lt;H3&gt;<\/b><b> Specialist Press vs Mass Media<\/b><\/p>\n<p><span style=\"font-weight: 400;\">The highly technical nature of the pharmaceutical industry is reflected in its media coverage. Scientific and specialist press account for 45% of all industry coverage. This significant proportion demonstrates the importance of expert perspectives in pharmaceutical communications.<\/span><\/p>\n<h3><b>Priority Topics in Professional Coverage<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Three categories dominate professional pharmaceutical industry media coverage:<\/span><\/p>\n<ul>\n<li aria-level=\"1\"><b>Business news leads reporting, with focus on:<\/b><\/li>\n<\/ul>\n<ol>\n<li style=\"list-style-type: none;\">\n<ol>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Financial results<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Mergers and acquisitions<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Market share developments<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">IPO activities<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<ul>\n<li aria-level=\"1\"><b>R&amp;D developments maintain steady coverage through:<\/b><\/li>\n<\/ul>\n<ol>\n<li style=\"list-style-type: none;\">\n<ol>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Clinical trial updates<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Pipeline announcements<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Portfolio developments<\/span><span style=\"font-weight: 400;\">\n<p><\/span><\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<ul>\n<li aria-level=\"1\"><b>New product launches generate significant attention:<\/b><\/li>\n<\/ul>\n<ol>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Novel molecule introductions<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Treatment breakthroughs<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"2\"><span style=\"font-weight: 400;\">Innovation in medication delivery systems<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<p><span style=\"font-weight: 400;\">This more technical, business-focused coverage provides a striking contrast to the COVID-dominated social media narrative, highlighting the gap between professional discourse and public perception.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><b>Download the Full Pharmaceutical Industry Media Coverage Report<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">For comprehensive insights into the transformation of pharmaceutical industry media coverage, including detailed analysis of eight major companies, <\/span><b>download the full report.<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Complete share of voice data across eight major pharma brands<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Emerging conversation trends<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Top ranking drugs by mention volume<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Key journalist contacts<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Upcoming, relevant industry events<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">The full report provides detailed analysis of:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">COVID-related events that drove pharmaceutical industry media coverage<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The GLP-1 weight-loss medication revolution in the media<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Company-specific social media and news coverage data<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Complete breakdown of discussion patterns across all major pharmaceutical topics<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Comprehensive media monitoring insights across mainstream and social channels<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Download the complete<\/span><a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/pharma-industry-media-analysis\/\"><b> pharmaceutical industry media coverage report now<\/b><span style=\"font-weight: 400;\">. <\/span><\/a><\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":33,"featured_media":54763,"comment_status":"closed","ping_status":"open","sticky":false,"template":"blog-post-new-template.php","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"audience":[585,584,380],"topic":[1335,1336],"region":[],"class_list":["post-55165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","audience-industry","audience-pharma","audience-pr-agencies-2","topic-brand-reputation-management-en-gb","topic-competitive-intelligence-en-gb"],"acf":[],"_links":{"self":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/posts\/55165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/comments?post=55165"}],"version-history":[{"count":0,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/posts\/55165\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/media\/54763"}],"wp:attachment":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/media?parent=55165"}],"wp:term":[{"taxonomy":"audience","embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/audience?post=55165"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/topic?post=55165"},{"taxonomy":"region","embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/region?post=55165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}